PF-Atlas › Clinical Trials › NCT06132256

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis

Axatilimab · Phase 2

Registry ID

NCT06132256

Phase

Phase 2

Status

Active, not recruiting

Drug / intervention

Axatilimab

Sponsor

Syndax Pharmaceuticals

Start

2023-12-11

Enrollment

145

Locations

About this trial

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

View NCT06132256 on ClinicalTrials.gov →

Explore related

All Axatilimab trials All IPF trials

Related trials

Axatilimab — NCT07011810

Medical disclaimer. This page summarizes public trial data for NCT06132256 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.